Murat Araz

Treatment Sequencing of CDK4/6 Inhibitors in Bone-Only Hormone Receptor-Positive Metastatic Breast Cancer: Multi-Center Real-World Data Revealing a Numerical Trend Favoring Later-Line Use

Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy represent the gold standard in the first-line treatment of hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC). However, the optimal timing of CDK4/6i initiation...